Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 213 matching trials from the live ClinicalTrials.gov search.
Conditions
Type2diabetes, Mild Cognitive Impairment, Age-related Cognitive Decline
Interventions
Progressive Exercise Program (12 Weeks)
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Endocrine Dysfunction, Trauma, Brain Injury
Interventions
Androgel (Testosterone Gel), Placebo gel
Drug · Other
Lead sponsor
Craig Hospital
Other
Eligibility
16 Years to 65 Years · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Englewood, Colorado
Completed No phase listed Observational

DHS MIND Metabolomics

NCT03975309
Conditions
Diabetes
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Diagnostic Test · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
New York, New York
Recruiting Phase 1 Interventional

Diagnosis of Pheochromocytoma

NCT00004847
Conditions
Pheochromocytoma, Endocrine Disease, Endocrine Diseases
Interventions
([18F]-DOPA), ([18F]-6F-DA)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 120 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2048
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Gestational Diabetes, Endothelial Dysfunction, Physical Inactivity
Interventions
Insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Recruiting No phase listed Observational Accepts healthy volunteers

Wake Forest Alzheimer's Disease Clinical Core

NCT03140865
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2031
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Type 2 Diabetes, Microvascular Dysfunction
Interventions
Intensive risk factor management
Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Anovulation
Interventions
Anastrozole 1 mg, Anastrozole 5 mg, Anastrozole 10 mg, Clomiphene Citrate 50 mg, Clomiphene Citrate 100 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rockland, Massachusetts
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of Adults With Endocrine and Metabolic-Related Conditions

NCT02830308
Conditions
Endocrine Diseases
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated No phase listed Observational Accepts healthy volunteers

Leukocyte Dysfunction in Diabetic Patients.

NCT01144520
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Sashwati Roy
Other
Eligibility
40 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

GLP-1 and Hypoglycemia

NCT01858896
Conditions
Type 2 Diabetes Mellitus
Interventions
Glucagon-Like Peptide- 1 (GLP-1) infusion, Placebo Comparator: Saline Infusion
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Diabetes Insipidus, Diabetes Insipidus, Neurohypophyseal
Interventions
chlorpropamide, desmopressin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
6 Months to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Chicago, Illinois
Completed No phase listed Observational Accepts healthy volunteers

Glucose Variability and Cognition in Prediabetes

NCT04201600
Conditions
Glucose Metabolism Disorders (Including Diabetes Mellitus), Cognitive Decline, PreDiabetes, Aging, Alzheimer's Disease
Interventions
Continuous Glucose Monitoring System (CGMS)
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
50 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm, Neuroendocrine Neoplasm, Recurrent Adult Soft Tissue Sarcoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Colorectal Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Pancreatic Carcinoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
Interventions
Pharmacological Study, Romidepsin
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
11
States / cities
Duarte, California • Sacramento, California • Atlanta, Georgia + 8 more
Conditions
Urinary Retention, Neurogenic Bladder
Interventions
C2P
Device
Lead sponsor
Spinal Singularity
Industry
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Peoria, Arizona • Surprise, Arizona • Downey, California + 5 more
Completed No phase listed Observational Accepts healthy volunteers

Continuous Glucose Monitoring in Type 2 Diabetes Mellitus

NCT01083043
Conditions
Diabetic Vascular Complications
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Mineola, New York
Conditions
Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Exendin-4 SC, Placebo SC
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

NCT02406586
Conditions
Hypertension, Diabetes
Interventions
Salsalate, Carvedilol, Placebo, Intralipid 20%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
15 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Ann Arbor, Michigan
Active, not recruiting Phase 2 Interventional

Immune Disorder HSCT Protocol

NCT01821781
Conditions
Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Hyper-IgM, DiGeorge Syndrome, Chediak-Higashi Syndrome, Common Variable Immune Deficiency, Immune Dysregulatory Disorders, Hemophagocytic Lymphohistiocytosis, IPEX, Autoimmune Lymphoproliferative Syndrome, X-linked Lymphoproliferative Syndrome
Interventions
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Diabetes, Cancer, Multiple Sclerosis, Arthritis, Parkinson's Disease, Cognitive Disorders, Brain Injury, Stroke
Interventions
Exergame, Home based balance training
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Tucson, Arizona